PDF(Pubmed)
Abstract：
UNASSIGNED: It remains controversial whether it is better to continue oral low-dose aspirin (LDA) during the perioperative period in spinal surgery. This study aims to evaluate the safety of continued LDA administration in the perioperative periods of microendoscopic laminectomy (MEL) by assessing perioperative complications and clinical outcomes.
UNASSIGNED: We ultimately included 88 patients (35 males, 53 females) who underwent one level of MEL for lumbar spinal canal stenosis from April 2016 to March 2022. Patients who did not undergo anticoagulation therapy were classified into Group A (65 patients), those who stopped anticoagulation therapy at the perioperative periods were classified into Group B (9 patients), and those who continued oral administration of LDA throughout the perioperative periods were classified into Group C (14 patients). Surgery time, intraoperative estimate blood loss (EBL), differences between hemoglobin (Hb) and platelet (Plt) before and after surgery, perioperative complications, and cross-sectional area of hematoma and dural sac on MRI taken within 1 week and at 6 months or more after surgery were assessed between three groups. The EuroQol-5 dimensions (EQ-5D), Oswestry Disability Index (ODI), and Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ) were also evaluated as the clinical outcomes.
UNASSIGNED: There was no statistically significant difference between the three groups in operation time, intraoperative EBL, differences between Hb and Plt before and after surgery, and cross-sectional area of hematoma and dural sac on MRI. A case of hematoma removal was confirmed in Group A. There was also no statistically significant difference between the three groups in EQ-5D, ODI, and each domain of JOABPEQ.
UNASSIGNED: The continuation of LDA throughout the perioperative periods did not affect perioperative complications and clinical outcomes of one-level MEL. In MEL, it might be possible to continue oral administration of LDA throughout the perioperative periods.
UNASSIGNED: We ultimately included 88 patients (35 males, 53 females) who underwent one level of MEL for lumbar spinal canal stenosis from April 2016 to March 2022. Patients who did not undergo anticoagulation therapy were classified into Group A (65 patients), those who stopped anticoagulation therapy at the perioperative periods were classified into Group B (9 patients), and those who continued oral administration of LDA throughout the perioperative periods were classified into Group C (14 patients). Surgery time, intraoperative estimate blood loss (EBL), differences between hemoglobin (Hb) and platelet (Plt) before and after surgery, perioperative complications, and cross-sectional area of hematoma and dural sac on MRI taken within 1 week and at 6 months or more after surgery were assessed between three groups. The EuroQol-5 dimensions (EQ-5D), Oswestry Disability Index (ODI), and Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ) were also evaluated as the clinical outcomes.
UNASSIGNED: There was no statistically significant difference between the three groups in operation time, intraoperative EBL, differences between Hb and Plt before and after surgery, and cross-sectional area of hematoma and dural sac on MRI. A case of hematoma removal was confirmed in Group A. There was also no statistically significant difference between the three groups in EQ-5D, ODI, and each domain of JOABPEQ.
UNASSIGNED: The continuation of LDA throughout the perioperative periods did not affect perioperative complications and clinical outcomes of one-level MEL. In MEL, it might be possible to continue oral administration of LDA throughout the perioperative periods.
摘要：
■在脊柱外科手术的围手术期是否更好地继续口服低剂量阿司匹林（LDA）仍然存在争议。本研究旨在通过评估围手术期并发症和临床结果，评估显微内窥镜椎板切除术（MEL）围手术期持续使用LDA的安全性。
■我们最终纳入了88名患者（35名男性，53名女性），从2016年4月至2022年3月因腰椎管狭窄而接受了一级MEL。未接受抗凝治疗的患者分为A组（65例），将围手术期停止抗凝治疗的患者分为B组（9例），在整个围手术期持续口服LDA的患者被分为C组(14例).手术时间,术中估计失血量（EBL），手术前后血红蛋白（Hb）和血小板（Plt）的差异，围手术期并发症,评估三组间在手术后1周内和6个月或更长时间的MRI上的血肿和硬膜囊横截面积。EuroQol-5尺寸（EQ-5D），Oswestry残疾指数（ODI），和日本骨科协会背痛评估问卷(JOABPEQ)也被评估为临床结局。
■三组手术时间差异无统计学意义,术中EBL,手术前后Hb和Plt的差异，MRI上血肿和硬膜囊的横截面积。A组确认血肿清除1例,EQ-5D三组间亦无统计学差异,ODI,和JOABPEQ的每个域。
■在整个围手术期继续使用LDA并不影响一级MEL的围手术期并发症和临床结局。在MEL,有可能在整个围手术期继续口服LDA.
■我们最终纳入了88名患者（35名男性，53名女性），从2016年4月至2022年3月因腰椎管狭窄而接受了一级MEL。未接受抗凝治疗的患者分为A组（65例），将围手术期停止抗凝治疗的患者分为B组（9例），在整个围手术期持续口服LDA的患者被分为C组(14例).手术时间,术中估计失血量（EBL），手术前后血红蛋白（Hb）和血小板（Plt）的差异，围手术期并发症,评估三组间在手术后1周内和6个月或更长时间的MRI上的血肿和硬膜囊横截面积。EuroQol-5尺寸（EQ-5D），Oswestry残疾指数（ODI），和日本骨科协会背痛评估问卷(JOABPEQ)也被评估为临床结局。
■三组手术时间差异无统计学意义,术中EBL,手术前后Hb和Plt的差异，MRI上血肿和硬膜囊的横截面积。A组确认血肿清除1例,EQ-5D三组间亦无统计学差异,ODI,和JOABPEQ的每个域。
■在整个围手术期继续使用LDA并不影响一级MEL的围手术期并发症和临床结局。在MEL,有可能在整个围手术期继续口服LDA.
